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Abstract: Traumatic brain injury (TBI) is one of the leading causes of death and disability worldwide.
Our understanding of its pathobiology has substantially increased. Following TBI, the following
occur, edema formation, brain swelling, increased intracranial pressure, changes in cerebral blood
flow, hypoxia, neuroinflammation, oxidative stress, excitotoxicity, and apoptosis. Experimental
animal models have been developed. However, the difficulty in mimicking human TBI explains why
few neuroprotective strategies, drawn up on the basis of experimental studies, have translated into
improved therapeutic strategies for TBI patients. In this study, we retrospectively examined brain
samples in 145 cases of death after different survival times following TBI, to investigate aquaporin-4
(AQP4) expression and correlation with hypoxia, and neuroinflammation in human TBI. Antibodies
anti-glial fibrillary acid protein (GFAP), aquaporin-4 (AQP4), hypoxia induced factor-1α (HIF-1α),
macrophage/phagocytic activation (CD68), ionized calcium-binding adapter molecule-1 (IBA-1), and
neutrophils (CD15) were used. AQP4 showed a significant, progressive increase between the control
group and groups 2 (one-day survival) and 3 (three-day survival). There were further increases
in AQP4 immunopositivity in groups 4 (seven-day survival), 5 (14-dayssurvival), and 6 (30-day
survival), suggesting an upregulation of AQP4 at 7 to 30 days compared to group 1. GFAP showed its
highest expression in non-acute cases at the astrocytic level compared with the acute TBI group. Data
emerging from the HIF-1α reaction showed a progressive, significant increase. Immunohistochemistry
with IBA-1 revealed activated microglia starting three days after trauma and progressively increasing
in the next 15 to 20 days after the initial trauma. CD68 expression demonstrated basal macrophage
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and phagocytic activation mostly around blood vessels. Starting from one to three days of survival
after TBI, an increase in the number of CD68 cells was progressively observed; at 15 and 30 days of
survival, CD68 showed the most abundant immunopositivity inside or around the areas of necrosis.
These findings need to be developed further to gain insight into the mechanisms through which brain
AQP4 is upregulated. This could be of the utmost clinicopathological importance.
Keywords: traumatic brain injury; aquaporin; genetic analysis; edema; computed tomography (CT)
scan; hypoxia; microglia activation
1. Introduction
Current estimates from the World Health Organization (WHO) suggest that traumatic brain injury
(TBI) will be the third leading cause of death and disability by the year 2020 [1,2]. Peeters et al. reported
an average mortality rate of 10.53 per 105 per year [3]. However, it is still difficult to calculate an
average incidence and mortality rate since there is considerable variation in case definitions, including
criteria and methods used in the studies [4].
Our understanding of the pathological mechanisms of TBI has substantially increased. However,
many in-depth studies are needed, since the complex cascade of physiological and biochemical
mechanisms in TBI are only partially understood.
The negative effects of brain trauma are determined not only by the entity of the primary injury
resulting from a direct or indirect biomechanical force on the brain matter. Secondary events, such
as edema formation, brain swelling, increased intracranial pressure, changes in cerebral blood flow
associated with hypoxia, neuroinflammation, oxidative stress, excitotoxicity, and apoptosis [5,6], may
occur with some delay, and may greatly affect the patient’s outcome [7]. Regardless of the cause of
brain injury, brain edema almost always occurs and is heavily involved in the pathophysiology of
brain damage following traumatic injury, being a central part of the vicious cycle of injury in TBI and
the major determinant of patient prognosis [7–12].
Brain edema is caused by a synergy of molecular, cellular, structural, and functional changes
in blood–brain barrier (BBB) function, microcirculation, and mediators, variously interacting in the
different types of cerebral edema as first identified by Klatzo and subsequently modified [13,14]. In an
animal model of TBI, Blixt et al. demonstrated that disintegration of the BBB was associated with
increased permeability leading to an increased presence of immunoglobulin G (IgG) in the brain
parenchyma at least four days post TBI [15].
Following TBI, brain edema occurs with vasogenic edema occurring rapidly after the
injury, primarily in the center of the lesion, whereas cytotoxic edema has a later onset and is
predominant [16,17]. There is growing evidence that members of aquaporins (small, hydrophobic
membrane proteins regarded as a ‘pure water channel family’ that facilitate water transport) play an
important role in traumatic brain edema [18–22].
Of these, aquaporin-4 (AQP4), the most abundant aquaporin in the brain [23], is the dominant
contributor to the regulation of cerebral edema [24]. A biphasic role of AQP4 has been hypothesized:
a negative role during edema formation and a positive role in the resolution phase [25]. Moreover,
cross-talk between astrocyte activation, AQP expression, brain inflammation, and hypoxia exists in
brain response to trauma [26,27] and this needs to be further clarified to gain a better understanding of
the roles played by several mediators in the regulation of ion/water homeostasis in brain contusive
injury. To achieve this depth of knowledge, it is of the utmost importance to consider that, in the
brain, a complex network of neurons acts as a functional structure interacting with glial cells (i.e.,
astrocytes), cerebral blood vessels, and endothelial cells, and as part of a single physiological entity,
the neurovascular unit (NVU) [28].
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Experimental animal models of TBI have been developed, significantly advancing our
understanding of the pathophysiology of TBI and, consequently, the development of many potential
neuroprotective therapeutic strategies [29]. However, a deep translational gap still exists and few
neuroprotective strategies have been translated into improved clinical care for patients with acute head
trauma and other brain injuries [29]. One of the existing barriers is the lack of correspondence between
traditional experimental models and the conditions experienced in real-life accidents [29]. Most human
TBIs are due to blunt, nonpenetrating trauma, whereas most experimental animal models require
fixation of the head in a stereotaxic frame or the creation of a cranial window [29]. In experimental
animal models, a prolonged general anesthesia is used, which might potentially limit studies as
anesthetic agents can influence the pathophysiology of secondary TBI [30]. Animal models closer
to the reality of human TBI have been developed [29], minimizing the time of anesthesia, avoiding
pre-injury surgery, and allowing the mouse head and body to be freely mobile during impact. These
models showed a temporal course in the changes in AQP4 expression and localization after mild
and moderate TBI. Several human studies have been conducted on traumatic patients exploring the
cellular and molecular response of human brain tissue to traumatic injury. Fleming et al. explored
the cellular inflammatory response in human spinal cords after traumatic injury [31], demonstrating
an early activation of neutrophils and microglia, and subsequently generating a panel of oxidative
and proteolytic enzymes that may cause secondary injury by enlarging the lesion and potentially
worsening neurological dysfunction. The final conclusions provided an accurate view of the time
course of the cellular inflammatory response after human spinal cord trauma, supporting the data that
the critical time point for limiting neutrophil entry is within the first three days, ideally commencing
within 12 h of injury. In surgical brain specimens from blunt traumatic patients, Suzuki et al. [32]
demonstrated that vascular endothelial growth factors (VEGF), AQP1, and AQP4 were co-expressed in
astrocytes located in the edematous tissue, confirming that astrocytes expressing AQPs and VEGF play
a regulatory role in the water in- and out-flow in the injured tissue—a critical factor in the formation
and resolution of brain edema. Another study performed on the contusioned cortex of human TBI
focused on the degeneration and downregulation of astrocytes in traumatized brain leading to a
reduction in the cellular expression of glutamate transporters, contributing to posttraumatic elevation
of extracellular glutamate in humans [33]. A review study performed on brain surgical specimens
from blunt traumatic patients provided evidence of the multifaceted role of astrocyte cells in severe
traumatic human brain injuries [34–39].
In this study, we retrospectively examined brain samples in cases of death after different survival
times following TBI to investigate AQP4 expression and correlation with neuroinflammation and
hypoxia, to provide evidence of the complex role of AQP4 in human blunt TBI. To obtain data not
related to genetic variants, the human AQP4 gene (18q11.2–q12.1) was analyzed. On this basis, we
investigated the presence of this single nucleotide polymorphism (SNP) on the AQP4 gene in our study
population, excluding all samples with this genetic variant.
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2. Results
2.1. Genetic Analysis
In our cohort, we found 13 patients that were heterozygous for rs 3906956 T > C polymorphism in
exon 4 of the AQP4 gene (Figure 1). This variant was previously reported as the cause of increasing
water permeability in relation to its location in the C-terminal domain. Therefore, we excluded these
cases. As previously described, the C-terminal exon 4 includes phosphorylation sites (Ser276 and
Tyr277) that could be associated with water permeability. In the Human Gene Mutation Database
(www.hgmd.cf.ac.uk), only one naturally-occurring nonsynonymous single-nucleotide polymorphism
(nsSNP) (rs 3906956, M278T) was previously reported in the AQP4 gene, which could be potentially
associated with changes in protein function, increasing water permeability [40]. We found 13 patients
that were heterozygous for rs 3906956 T > C polymorphism in exon 4 of the AQP4 gene. These patients
were excluded because cases with edema could be related to inherent causes.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  4 of 18 
 
 
Figure 1. Aquaporin-4 (AQP4) DNA sequence in a wild type and a heterozygous individual. (A) DNA 
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DNA sequence electropherogram showing the heterozygous rs 3906956 T > C in the individual with 
increased water permeability (red arrow). 
2.2. Evaluation of Brain Edema from CT Scans 
Based on the available CT scans, edema/brain water burden was assessed semiquantitatively on 
a scale of 0 to 3, as a modification of Ito et al.: −: no detectable signs of edema; +/−: cortical sulci, 
Sylvian fissure, and third ventricle and perimesencephalic cistern compressed, but visible, in CT 
scans (Figure 2); ++: one or two of the above structures not visible (Figure 3); and +++: three or four of 
these structures not visible (Figures 2–4). 
 
Figure 2. (A) The axial computed tomography (CT) scans evidence diffuse edema with cortical sulci, 
Sylvian fissure, third ventricle, and perimesencephalic cistern compressed but still visible. White 
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increased ater per eability (red arrow).
2.2. Evaluation of Brain Edema from CT Scans
Based on the available CT scans, edema/brain water burden was assessed semiquantitatively on
a scale of 0 to 3, as a modification of Ito et al.: −: no detectable signs of edema; +/−: cortical sulci,
Sylvian fissure, and third ventricle and perimesencephalic cistern compressed, but visible, in CT scans
(Figure 2); ++: one or two of the above structures not visible (Figure 3); and +++: three or four of these
structures not visible (Figures 2–4).
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Figure 2. ( ) The axial co puted to ography (CT) scans evidence diffuse ede a ith cortical sulci,
Sylvian fissure, third ventricle, and perimesencephalic cistern compressed but still visible. White arrow
on the left scan shows the perimesencephalic cisterns, while white arrows on the right scan show the
cortical sulci, third ventricle, and Sylvian fissure from left to right, respectively. (B) CT scan of a control
case. The cortical sulci (red arrow), the perimesencephalic cisterns (white arrow), the Sylvian fissure
(yellow arrow), and third ventricle (green arrow with dotted line) are clearly visible. No radiological
sign of edema is evidenced.
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Figure 4. The axial CT scans evidence diffuse brain edema and swelling, with severe midline shift due 
to multiple brain contusions and acute subdural and subarachnoid hemorrhage. Cortical sulci, 
Sylvian fissure, third ventricle, and perimesencephalic cistern are either compressed or not visible. 
From left to right side yellow arrows show the third ventricle compressed and dislocated and the 
cortical sulci compressed and pushed toward the skull. 
The weight of the brains was carefully evaluated and estimated in the TBI groups and control 
group (Figure 5). Table 1 summarizes the results. 
i re 3. The axial CT scans evidence iffuse edema with subarac noid and intracerebral hemorrhage:
cortical sulci (blue rrow), and perimesencephalic cisterns (red arrow) are not visible, while Sylvian
fissure (yellow arrow) and third ventricle (white arrow) are compressed but still visible.
Int. J. Mol. Sci. 2018, 19, 3544 6 of 19
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  5 of 18 
 
arrow on the left scan shows the perimesencephalic cisterns, while white arrows on the right scan 
show the cortical sulci, third ventricle, and Sylvian fissure from left to right, respectively. (B) CT scan 
of a control case. The cortical sulci (red arrow), the perimesencephalic cisterns (white arrow), the 
Sylvian fissure (yellow arrow), and third ventricle (green arrow with dotted line) are clearly visible. 
No radiological sign of edema is evidenced. 
 
Figure 3. The axial CT scans evidence diffuse edema with subarachnoid and intracerebral 
hemorrhage: cortical sulci (blue arrow), and perimesencephalic cisterns (red arrow) are not visible, 
while Sylvian fissure (yellow arrow) and third ventricle (white arrow) are compressed but still visible. 
 
Figure 4. The axial CT scans evidence diffuse brain edema and swelling, with severe midline shift due 
to multiple brain contusions and acute subdural and subarachnoid hemorrhage. Cortical sulci, 
Sylvian fissure, third ventricle, and perimesencephalic cistern are either compressed or not visible. 
From left to right side yellow arrows show the third ventricle compressed and dislocated and the 
cortical sulci compressed and pushed toward the skull. 
The weight of the brains was carefully evaluated and estimated in the TBI groups and control 
group (Figure 5). Table 1 summarizes the results. 
i . i l i iff i lli , it i li ift
t ultiple brain contusions and acute subd ral and subarachnoid hemorrhage. Cortical sulci, Sylvian
fissure, third ventricle, a d perimesencephalic istern are either compr ssed or not visible. From left
to right side yellow arrows show the third ventricle compressed and dislocated and the cortical sulci
mpressed and pushed toward t e skull.
i t f t r i r f ll l t ti t i t I r tr l
( i ). l s ri s t res lts.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  6 of 18 
 
 
Figure 5. Brain weight: the differences among multiple groups were assessed using one-way analysis 
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Table 1. Brain weight and computed tomography (CT) determination of edema/brain water burden. 
Group Number of Cases 
GCS 
Evaluation 
Time of Death After 
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Water Burden Brain Weight 
1 25 Not evaluated Almost immediate +/− 1280 ± 296 g 
2 24 4–8 1 day (20 ± 6 h) ++ 1320 ± 380 g 
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2.3. Histological Examination 
In group 1 (immediate death), histological examination of the contusion areas showed evidence 
of a hemorrhagic core with abundant necrotic tissue. The areas of necrosis became surrounded by 
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Histological features of brain edema in the pericontusion areas became more evident in groups 
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by the appearance of swollen astrocytes and shrinkage of the neurons that become eosinophilic, with 
pyknosis of the nuclei (group 3). Vacuolated spaces around blood vessels were also present in both 
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Table 1. Brain weight and computed tomography (CT) determination of edema/brain water burden.
Group Number ofCases
GCS
Evaluation
Time of Death After
Trauma
Edema/Brain
Water Burden Brain Weight
1 25 Not evaluated Almost immediate +/− 1280 ± 296 g
2 24 4–8 1 day (20 ± 6 h) ++ 1320 ± 380 g
3 24 3–8 3 days (72 ± 10 h) ++ 1336 ± 334 g
4 24 3–8 7 days (6 ± 2 days) +++ 1384 ± 400 g
5 24 3–8 14 days (14 ± 4 days) +++ 1386 ± 364 g
6 24 3–8 30 days (30 ± 10 days) +++ 1410 ± 304 g
7 (Control) 25 Not evaluated Not determined +/− 1200 ± 234 g
Based on the available CT scans, edema/brain water burden was assessed semiquantitatively on a scale of 0–3,
as a modification of Ito et al. as follows: − no detectable signs of edema; +/− cortical sulci, Sylvian fissure, third
ventricle, and perimesencephalic cistern compressed, but visible, in CT scans; ++ one or two of the above structures
not visible; +++ three or four of these structures not visible [39]. GCS—Glasgow Coma Scale.
2.3. Histological Examination
In group 1 (immediate death), histological examination of the contusion areas showed evidence
of a hemorrhagic core with abundant necrotic tissue. The areas of necrosis became surrounded by
inflammatory cells, such as neutrophils and macrophages, starting from one day of survival after
injury (group 2). In the control group and group 1, neutrophils were all intravascular. They became
increasingly evident around the margin of the necrotic areas; group 4 (seven day survival) showed the
most abundant macrophages inside or around the areas of necrosis. Weeks after TBI (groups 5 and 6),
only a few scattered neutrophils were observed through the reparative or cystic areas.
Histological features of brain edema in the pericontusion areas became more evident in groups
2 and 3 where swelling of the astrocytes and the neuronal dendrites was present (group 2) followed
by the appearance of swollen astrocytes and shrinkage of the neurons that become eosinophilic, with
pyknosis of the nuclei (group 3). Vacuolated spaces around blood vessels were also present in both
groups. Similar histological findings were observed in more distant areas and in the contralateral
tissue samples. In groups 4, 5, and 6 (7, 14, and 30 days’ survival, respectively) the swelling of
astrocytes and neurons remained evident for all regions assessed. An increasing proliferation of
reactive astrocytes in the tissue proximal to the contusion was detected; at high magnification and on
confocal three-dimensional analysis, astrocytes became visibly larger with increased soma sizes and
thickened processes.
2.4. Immunohistochemistry
The immunohistochemical study of brain areas samples from the different groups produced the
results as shown in Table 2.
Table 2. Semiquantitative evaluation and statistical analysis of the immunohistochemical findings and
gradation of the immunohistochemical reaction in the brain samples.
Antibody Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 (Control)
AQP4 +/− +++ +++ ++++ ++++ ++++ +/−
HIF-1α +/− ++ +++ +++ ++ ++ −
GFAP +/− ++ +++ +++ ++++ ++++ +/−
CD68 +/− + +++ +++ ++++ ++++ +/−
IBA-1 +/− ++ +++ +++ +++ +++ +/−
CD15 +/− ++ +++ +++ ++ ++ −
Analysis of the immunohistochemical findings and gradation of the immunohistochemical reactions. Responses
for antibodies anti-aquaporin-4 (AQP4), anti-hypoxia induced factor-1α (HIF-1α), anti-glial fibrillary acid protein
(GFAP), anti-macrophages (CD68), anti-ionized calcium-binding adapter molecule-1 (IBA-1), and anti-neutrophils
(CD15) expressions in brain specimens. Intensity of immunopositivity was assessed semiquantitatively in the
scale of 0 to 4 as follows, −: no immunoreactivity (0%); +: mild immunopositivity in scattered cells (10%); ++:
immunopositivity in up to one third of cells (33%); +++: immunopositivity in up to two-third of cells (70%); and
++++: strong immunopositivity in the majority or all cells (100%). In cases of divergent scoring, a third observer
decided the final category.
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Immunohistochemistry was used to determine whether the expression of AQP4 changed at
different time points of survival. An injury-induced increase in AQP4 immunopositivity was observed
(control group versus all trauma groups p < 0.01, except for group 1, almost immediate death). When
comparing the different groups, a significant (p < 0.001) increase in AQP4 immunostaining was detected
between group 2 (one day survival) and 3 (three day survival), and between group 2 and 4 (seven day
survival), thus suggesting an upregulation of AQP4 at three to seven days compared to one day. There
were increases in AQP4 immunopositivity in group 5 (14 days survival), and the p-value was 0.0016.
A significant increase was seen between groups 2, 3, and 4 and groups 5 and 6 (30 day survival), thus
suggesting an upregulation of AQP4 at 15 to 30 days compared to one day (Figure 6A–D).
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HIF-1α immunoexpression increased significantly at early time points of survival (one and three’
days survival, group 2 and 3) and in group 4 compared to control cases (group 7) and immediate
deaths (group 1). Lesser statistical significance was seen when group 1 was compared with groups 5
and 6 (Figure 7A–C).
A significant (p < 0.05) increase in anti-GFAP immunopositivity was observed in all groups
compared to group 1 and the control group, where a basal, perivascular GFAP immunopositivity was
observed. Statistical analysis showed significant post-injury time effects on GFAP immunoexpression
between groups 2, 3, and 4 (p < 0.001), suggesting an upregulation of GFAP expression at 72 h compared
to 24 h. Significant increases in GFAP immunopositivity (p < 0.001) were observed in groups 5 and
6 (14 and 30 days following TBI) when compared to groups 1 and 2. The corresponding histological
observation showed that GFAP staining darkened and astrocytes became larger and entangled; at high
magnification, astrocytes became visibly larger with increased soma sizes and thickened processes
(Figure 8A–C).
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In control cases and in group 1, a basal macrophage/phagocytic activation immunopositivity
was observed mostly around blood vessels. Starting from one to three days of survival after TBI,
an increase in the number of CD68 cells was progressively observed in conjunction with a change in
their morphology. CD68+ cells became larger with shorter and thicker processes (Figure 9A). Groups 5
and 6 (15 and 30 days’ survival) showed the most abundant CD68 immunopositivity inside or around
the areas of necrosis (Figure 9B).
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Immunopositivity to IBA-1 was observed in control cases and in group 1, with cells showing
dendritic morphology (Figure 9C). Starting from three days of survival after TBI, an increase in the
number of cells was progressively observed, which then stabilized in the further survival period
(groups 4, 5, and 6), in conjunction with the CD68+ cells, which progressively showed the most
abundant immunopositivity (Figure 9D).
The areas of necrosis became surrounded by inflammatory cells such as neutrophils labeled by
their expression of CD15 starting from one day of survival after injury (group 2). In the control group
and in group 1, neutrophils were all intravascular. They became increasingly evident around the
margin of the necrotic areas. Weeks after TBI (groups 5 and 6), only a few scattered neutrophils were
observed through the reparative or cystic areas (Figure 10).
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3. Discussion
In this study, we investigated the expression of AQP4, the primary water channel in the brain,
in fatal human traumatic brain injury at several evolution phases. The pathophysiology of traumatic
brain injury is complex. We analyzed the correlation between clinical and computed tomography (CT)
data with histological results to demonstrate the mechanisms by which brain AQP4 is upregulated. It is
thought that metabolic dysfunction, excitotoxicity, oxidative stress, edema formation, inflammation,
and cell death (necrosis and apoptosis, respectively) are involved [6,7]. Difficulty in the use of
inflammatory markers, such as immunohistochemical markers of TBI in the early stage, is due to an
overlap of secondary changes after traumatic event (e.g., hypoxia and edema) that can lead to difficulty
and errors in estimating survival time.
AQP4 shows a significant and progressive increase between control group and groups 2 (one
day survival) and 3 (three day survival), from the acute stages of the traumatic insult. There were
further increases in AQP4 immunopositivity in groups 4 (seven day survival), 5 (14 day survival), and
6 (30 day survival), suggesting an upregulation of AQP4 at 7 to 30 days compared to one day.
GFAP, characterized by later expression, showed its highest expression in group 5 (14 day survival)
and 6 (30 day survival) at the astrocytic level, compared with groups 1–3 and group 4 (seven day
survival). Astrocytic cell bodies enlarged and the astrocytic end-feet were thicker and prominent.
Data emerging from the HIF-1α reaction agreed with those reported in the literature, showing a
progressive, significant increase until group 4 (seven day survival). In hypoxia, upregulation of HIF-1α,
associated with disruption of BBB and increased permeability of blood vessels, has been linked to an
upregulation of AQP4, which involves astrocytes in brain edema [41].
As defined by Hoogland et al., microglial cells are defined as activated based on the following
criteria. (1) Microglia showed an activated morphology based on immunohistochemical staining, (2)
there was a significant increase in number and/or size of microglia compared to the control group,
and (3) there was a significant increase in expression of a microglial marker [42,43].
Our immunohistochemistry study with IBA-1 revealed that microglia were activated starting
three days after trauma and progressively increasing for the next 15 to 20 days after the initial trauma.
CD68 expression demonstrated a basal macrophage/phagocytic activation mostly around blood
vessels. Starting from one to three days of survival after TBI, an increase in the number of CD68
cells was progressively observed in conjunction with a change in their morphology: cells became
larger with shorter and thicker processes. At 15 and 30 days of survival, CD68 showed the most
abundant immunopositivity inside or around the areas of necrosis. At all time points microglia were
morphologically ramified with fine processes.
The areas of necrosis became surrounded by neutrophils (CD15) starting from one day of survival
after injury. They became increasingly evident around the margin of the necrotic areas (group 4,
seven day survival); only a few scattered neutrophils were observed through the reparative or cystic
areas weeks after TBI. The progressive increase in AQP4 we observed in the present retrospective
study, as opposed to most other studies, may be interpreted as variations in the temporal course of
injury following trauma. Other studies came to different conclusions. As described by Blixt [15],
in cytotoxic edema induced by ischemia, the amount of edema is reduced in AQP4 deficient animals,
water accumulation is intracellular, and astrocytes, normally diffusely populated by AQP4 channels,
would be protected from swelling in knockout models. Conversely, vasogenic edema increased in
AQP4 deficiency created by hydrostatic forces for a disrupted BBB; the explanation is that edema
is mainly extracellular and was conjectured to be cleared by fluid elimination through AQP4 water
channels located in the glial linings of the ventricles [15].
AQP water channels may have a pivotal role in maintaining water homeostasis in the brain [44],
and these channels have been demonstrated to be involved in the development and resolution of
cytotoxic and vasogenic edema [25,45,46]. AQP4 shows polarized distribution, being mainly expressed
in astrocyte foot processes surrounding capillaries; astrocyte processes, which comprise the glial
limiting membrane; and in ependymal cells, with microvilli expressing no AQP4 at all [47–49]. In many
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pathological conditions, a redistribution of AQP4 occurs in membrane domains apart from end-feet
areas, due to the degradation of the proteoglycan agrin by the matrix metalloproteinase 3 [29,50–52].
AQP4 is abundant at sites of fluid transport, including pial and ependymal surfaces in contact with
cerebrospinal fluid (CSF), subarachnoid space, and the ventricular system [48,53]. This distribution
indicates that AQP4 is crucial in maintaining water balance in the brain with a versatile function,
facilitating water fluxes into and out of the brain parenchyma [54]. Edema can be viewed as a
dysfunction of aquaporins to properly prevent or facilitate water movement [25].
An overexpression of AQP4 has been demonstrated in the reactive astrocytes after cerebral
injury [55]. AQP4 acts as bidirectional water transport, which enables it to contribute to both edema
formation at early time points, and the clearance of water from the brain into blood vessels at later time
points [56]. AQP4 is critical both in the movement of water into swelling astrocytes [45,57], as seen in
cellular cytotoxic edema, as well as in the resolution of vasogenic edema [47] after brain injury.
Pinchi et al. indicated that miR-21, miR-92, and miR-16 have a high predictive power in
discriminating trauma brain cases from controls and could be promising biomarkers as a strong
predictor of survival, and useful tools for post-mortem diagnosis of traumatic brain injury [58,59].
The presence of AQP4 seems to play an acute detrimental role, but at a later phase starting from around
seven days post injury and for at least one month. AQP4 may play a beneficial role that seems to be
related to the inhibition of microglia and promotion of edema resolution [60–63].
4. Materials and Methods
4.1. Study Population
The clinical data and the autopsy records of the autopsies performed in the Department of Forensic
Pathology of the Universities of Rome and Foggia, Italy, over the period of 1999 to 2015 were evaluated
retrospectively. We identified 388 cases in which contusive, nonpenetrating traumatic brain injury
was revealed as cause of death. Since age-related differences have been reported in post-traumatic
brain swelling and vascular changes after TBI [28,36–38], we excluded all TBI cases in infants and
children. In our selected cases, the age of the deceased ranged between 24 and 76 years. Only cases
with negative toxicology for drug and ethanol abuse were included in the study. For our study, we
excluded 13 patients with genetic polymorphism rs 3906956. Following these criteria, 145 cases were
selected for our retrospective analysis. In the final cohort, a total of 91 men and 54 women were
included, as reported in Table 3. We divided the study population into six groups, each consisting of
a similar number of cases, according to the survival interval after TBI. The control group (group 7)
included 25 cases, selected among sudden, nontraumatic deaths, with negative toxicological analysis,
in which no evidence of TBI was detected at post-mortem examination. The age of the control group
ranged between 20 and 71 years; 18 men and 7 women were included.
Table 3. Study population divided according to the survival interval after traumatic brain injury (TBI).
Group Number of Cases Sex Time of Death after Trauma
1 25 16 men; 9 women Almost immediate
2 24 15 men; 9 women 1 day (20 ± 6 h)
3 24 16 men; 8 women 3 days (72 ± 10 h)
4 24 17 men; 7 women 7 days (6 ± 2 days)
5 24 12 men; 12 women 14 days (14 ± 4 days)
6 24 15 men; 9 women 30 days (30 ± 10 days)
7 (Control) 25 18 men; 7 women Undetermined
The processing of the data reported in this paper was covered by the general authorization to
process personal data for scientific research purposes granted by the Italian Data Protection Authority
(1 March 2012 as published in Italy’s Official Journal no. 72 dated 26 March 2012), since the data do not
entail any significant personalized impact on data subjects.
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Our study did not involve the application of experimental protocols; therefore, it did not require
approval by an institutional and/or licensing committee. In all cases, local prosecutors opened an
investigation, ordering that an autopsy be performed to clarify the exact cause of death.
This investigation conforms to the principles outlined in the declaration of Helsinki.
4.2. Genetic Analysis
For each group, 10 sample blocks, sections of 10 µm were cut from each specimen with a new
sterile blade and outer sections were discarded. Four or five scrolls from serial sections were placed in
each tube (Eppendorf AG, Hamburg, Germany) for DNA extraction protocols.
4.2.1. DNA Extraction Protocols
We extracted the samples with QIAamp DNA Formalin-Fixed Paraffin-Embedded (FFPE) Tissue
Kit (Qiagen, Valencia, CA, USA), according to the manufacturer’s instructions with this modification:
the pellet was digested with a tissue lysis (ATL) buffer (Qiagen, Valencia, CA, USA) and proteinase
K overnight.
4.2.2. PCR Amplification and DNA Sequencing
We built primers for M278T SNP, allele A/G, rs 3906956, with Primer3web version 4.0.0
(ELIXIR, Tartu, Estonia). All primers were synthesized (Eurofins Genomics, Ebersberg, Bayern,
Germany): AQPEX4shortFw 5′ ≥ 3′ AAAGAAGCCTTCAGCAAAGC; AQPEX4shortRw 5′ ≥ 3′
GGTCAACGTCAATCACATGC. Polymerase chain reaction (PCR) was carried out using 50-µL volume
samples in a PCR thermocycler MasterCycler (Eppendorf AG, Hamburg, Germany). The PCR
conditions for the 35 cycles were denaturation 95 ◦C for 30 s, annealing 55 ◦C for 30 s, and extension
72 ◦C for 1 min. Each sample contained 0.1 mg genomic DNA, 10 pmol of each primer, 125 mM
deoxyribonucleoside triphosphate, 5 mM tris (hydroxymethyl) aminomethane (Tris) HCl (pH 8.3),
50 mM KCl, 1.5 mM MgCl2, and 1U Taq polymerase (Applied Biosystems, Foster City, CA, USA).
Amplified DNA fragments were subjected to direct cycle sequence analysis using the Taq dye-deoxy
terminator method with reverse primer (Applied Biosystems, Foster City, CA, USA) and an ABI PRISM
3100 Genetic Analyzer sequencer (Applied Biosystems, Foster City, CA, USA).
4.3. Evaluation of Edema CT Scan
Based on the available CT scans, edema/brain water burden was assessed semiquantitatively on
a scale of 0–3, modified from Ito et al.: −: no detectable signs of edema; +/−: cortical sulci, Sylvian
fissure, third ventricle and perimesencephalic cistern compressed, but visible, in CT scans; ++: one or
two of the above structures not visible; and +++: three or four of these structures not visible. The weight
of the brains had been carefully evaluated and estimated in the TBI groups and control group.
4.4. Histological and Immunohistochemical Analysis
We retrospectively examined brain samples taken at autopsy. Brain tissues from cases and controls
were fixed in 10% buffered formalin for 48 h. Then 4 µm-thick paraffin-embedded sections were cut and
stained with hematoxylin and eosin (H&E) stain. The areas of intense tissue injury, either in the form
of necrotic tissue (in the shorter survival cases) or as cystic change (in the longer surviving cases), were
excluded from immunohistochemical investigation. In addition, immunohistochemical investigation of
the grey matter of the frontal and temporal sections area was performed utilizing antibodies anti-glial
fibrillary acid protein (GFAP) (Agilent Dako, Copenhagen, Denmark), aquaporin-4 (AQP4) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), hypoxia induced factor-1α (HIF-1α) (Santa Cruz Biotechnology
Santa Cruz, CA, USA), macrophage/phagocytic activation (CD68) (Santa Cruz Biotechnology Santa
Cruz, CA, USA), ionized calcium-binding adapter molecule-1 (IBA-1) (Abcam, San Francisco, CA,
USA), and neutrophils CD15 (Agilent Dako, Copenhagen, Denmark). We used 4-µm-thick paraffin
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sections mounted on slides covered with (3-aminopropyl)triethoxysilane (Fluka, Buchs, Switzerland).
Pretreatment was necessary to facilitate antigen retrieval and to increase membrane permeability to
antibodies anti-AQP4, CD 15, and HIF-1α boiling in 0.25 M ethylene-diamine-tetraacetic acid (EDTA)
buffer, to antibodies anti-macrophage/phagocytic activation (CD68) and ionized calcium-binding
adapter molecule-1 (IBA-1) for 15 min in proteolytic enzyme (Agilent Dako, Copenhagen, Denmark),
at 20 ◦C. No pretreatment was necessary for antibody anti-GFAP. The dilution of primary antibody
was: CD15, 1:50 ratio; HIF-1α, 1:100 ratio; CD68 and IBA-1, 1:200 ratio; GFAP, 1:300 ratio; and AQP4,
1:500 ratio. The primary antibody was incubated for 120 min at 20 ◦C. The detection system utilized
was the labeled streptavidin-biotin (LSAB+) Kit (Agilent Dako, Copenhagen, Denmark), a refined
avidin-biotin technique in which a biotinylated secondary antibody reacts with several peroxidase
conjugated streptavidin molecules.
In addition, double antigen labeling, using antibody anti-AQP4, anti CD15, anti CD68, anti IBA-1
and anti GFAP, was performed.
The samples were examined under a confocal microscope True Confocal Scanner (Leica TCS SPE,
Milan, Italy), and a three-dimensional reconstruction was performed. A preliminary semiquantitative
evaluation of the immunohistochemical findings was performed by two different investigators
without prior knowledge. All measurements were taken using the same magnification of image
(10×) by the same two examiners. A third blind microscopic evaluator was involved to weigh the
histological evidence.
Statistical analysis of the immunohistochemical findings and gradation of the
immunohistochemical reactions was performed as follows. Responses about antibody anti-AQP4,
anti-GFAP, anti-HIF-1α, anti-CD68, anti-IBA-1, and anti-CD15 expressions in brain specimens
were evaluated, where NS (not significant): p > 0.05; * p < 0.05; ** p < 0.01; and *** p < 0.001.
Intensity of immunopositivity was assessed semiquantitatively on a 0–4 scale as follows, −: no
immunoreactivity (0%); +: mild immunopositivity in scattered cells (10%); ++: immunopositivity in up
to one third of cells (33%); +++: immunopositivity in up to two- third of cells (70%); and ++++: strong
immunopositivity in the majority or all cells (100%). In cases of divergent scoring, a third observer
decided the final category.
4.5. Statistical Analysis
The statistical analysis was assigned a numerical value from 0 to 5 for each single sample of
each group, according to the score attributed to the semi-quantitative evaluation. All the data was
presented as mean ±SE. Statistical analysis was performed with SPSS for Windows version 13.0 (SPSS
Inc., Chicago, IL, USA). The differences between multiple groups were assessed using a one-way
analysis of variance (ANOVA) with a significance level at p < 0.05. Post-hoc comparison between
groups was detected using the least significant difference (LSD) method.
5. Conclusions
Cerebral edema with brain swelling remains the most significant predictor of outcome in TBI.
Edema formation leads to an expansion of brain volume as it increases intracranial pressure, impairs
cerebral perfusion and oxygenation, and contributes to ischemic injuries and inflammatory response.
These findings need to be further examined to provide insight into the mechanisms by which
brain AQP4 is upregulated. This could be of utmost clinicopathological importance.
Author Contributions: M.N., A.F., E.T., S.C., L.C., M.D.P., P.F., R.L.R., A.M., M.S., A.S., F.S., R.Z. and V.F.
contributed to the conception and design of the work, and to the acquisition, analysis, and interpretation of
data for the work, drafted and revised it critically, approved the final version to be published, and agreed to be
accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of
the work are appropriately investigated and resolved. All authors reviewed and approved the final version of
the manuscript.
Funding: This research received no external funding. The authors received no financial support for the research,
authorship, and/or publication of this article.
Int. J. Mol. Sci. 2018, 19, 3544 16 of 19
Conflicts of Interest: The authors declare no conflicts of interest.
References
1. Nguyen, R.; Fiest, K.M.; McChesney, J.; Kwon, C.S.; Jette, N.; Frolkis, A.D.; Atta, C.; Mah, S.; Dhaliwal, H.;
Reid, A.; et al. The international incidence of traumatic brain injury: A systematic review and meta-analysis.
Can. J. Neurol. Sci. 2016, 43, 774–785. [CrossRef] [PubMed]
2. The Lancet Neurology. The changing landscape of traumatic brain injury research. Lancet Neurol. 2012, 11,
651. [CrossRef]
3. Peeters, W.; van den Brande, R.; Polinder, S.; Brazinova, A.; Steyerberg, E.W.; Lingsma, H.F.; Maas, A.I.
Epidemiology of traumatic brain injury in Europe. Acta Neurochir. (Wien.) 2015, 157, 1683–1696. [CrossRef]
[PubMed]
4. Tagliaferri, F.; Compagnone, C.; Korsic, M.; Servadei, F.; Kraus, J. A systematic review of brain injury
epidemiology in Europe. Acta Neurochir. (Wien.) 2006, 148, 255–268. [CrossRef] [PubMed]
5. Sharp, D.J.; Scott, G.; Leech, R. Network dysfunction after traumatic brain injury. Nat. Rev. Neurol. 2014, 10,
156–166. [CrossRef] [PubMed]
6. McGinn, M.J.; Povlishock, J.T. Pathophysiology of Traumatic Brain Injury. Neurosurg. Clin. N. Am. 2016, 27,
397–407. [CrossRef] [PubMed]
7. Golding, E.M. Sequelae following traumatic brain injury. The cerebrovascular perspective. Brain Res. Rev.
2002, 38, 377–388. [CrossRef]
8. Sviri, G.E. Massive cerebral swelling immediately after cranioplasty, a fatal and unpredictable complication:
Report of 4 cases. J. Neurosurg. 2015, 123, 1188–1193. [CrossRef] [PubMed]
9. Margulies, S.; Anderson, G.; Atif, F.; Badaut, J.; Clark, R.; Empey, P.; Guseva, M.; Hoane, M.; Huh, J.; Pauly, J.;
et al. Combination therapies for traumatic brain injury: Retrospective considerations. J. Neurotrauma 2016,
33, 101–112. [CrossRef] [PubMed]
10. Filippidis, A.S.; Liang, X.; Wang, W.; Parveen, S.; Baumgarten, C.M.; Marmarou, C.R. Real-time monitoring of
changes in brain extracellular sodium and potassium concentrations and intracranial pressure after selective
vasopressin-1a receptor inhibition following focal traumatic brain injury in rats. J. Neurotrauma 2014, 31,
1258–1267. [CrossRef] [PubMed]
11. Marmarou, C.R.; Liang, X.; Abidi, N.H.; Parveen, S.; Taya, K.; Henderson, S.C.; Young, H.F.; Filippidis, A.S.;
Baumgarten, C.M. Selective vasopressin-1a receptor antagonist prevents brain edema, reduces astrocytic
cell swelling and GFAP, V1aR and AQP4 expression after focal traumatic brain injury. Brain Res. 2014, 1581,
89–102. [CrossRef] [PubMed]
12. Ahmed, F.; Plantman, S.; Cernak, I.; Agoston, D.V. The temporal pattern of changes in serum biomarker
levels reveals complex and dynamically changing pathologies after exposure to a single low-intensity blast
in mice. Front. Neurol. 2015, 6, 114. [CrossRef] [PubMed]
13. Klatzo, I. Presidental address. Neuropathological aspects of brain edema. J. Neuropathol. Exp. Neurol. 1967,
26, 1–14. [CrossRef] [PubMed]
14. Qureshi, A.I.; Suarez, J.I. Use of hypertonic saline solutions in treatment of cerebral edema and intracranial
hypertension. Crit. Care Med. 2000, 28, 3301–3313. [CrossRef] [PubMed]
15. Blixt, J.; Svensson, M.; Gunnarson, E.; Wanecek, M. Aquaporins and blood–brain barrier permeability in
early edema development after traumatic brain injury. Brain Res. 2015, 1611, 18–28. [CrossRef] [PubMed]
16. Barzó, P.; Marmarou, A.; Fatouros, P.; Hayasaki, K.; Corwin, F. Biphasic pathophysiological response of
vasogenic and cellular edema in traumatic brain swelling. Acta Neurochir. Suppl. 1997, 70, 119–122. [PubMed]
17. Kawamata, T.; Katayama, Y.; Aoyama, N.; Mori, T. Heterogeneous mechanisms of early edema formation in
cerebral contusion: Diffusion MRI and ADC mapping study. Acta Neurochir. Suppl. 2000, 76, 9–12. [PubMed]
18. Badaut, J.; Fukuda, A.M.; Jullienne, A.; Petry, K.G. Aquaporin and brain diseases. Biochim. Biophys. Acta
2014, 1840, 1554–1565. [CrossRef] [PubMed]
19. Lv, Q.; Fan, X.; Xu, G.; Liu, Q.; Tian, L.; Cai, X.; Sun, W.; Wang, X.; Cai, Q.; Bao, Y.; et al. Intranasal delivery
of nerve growth factor attenuates aquaporins-4-induced edema following traumatic brain injury in rats.
Brain Res. 2013, 1493, 80–89. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 3544 17 of 19
20. Lo Pizzo, M.; Schiera, G.; Di Liegro, I.; Di Liegro, C.M.; Pál, J.; Czeiter, E.; Sulyok, E.; Dóczi, T. Aquaporin-4
distribution in control and stressed astrocytes in culture and in the cerebrospinal fluid of patients with
traumatic brain injuries. Neurol. Sci. 2013, 34, 1309–1314. [CrossRef] [PubMed]
21. Jullienne, A.; Badaut, J. Molecular contributions to neurovascular unit dysfunctions after brain injuries:
Lessons for target-specific drug development. Future Neurol. 2013, 8, 677–689. [CrossRef] [PubMed]
22. Shenaq, M.; Kassem, H.; Peng, C.; Schafer, S.; Ding, J.Y.; Fredrickson, V.; Guthikonda, M.; Kreipke, C.W.;
Rafols, J.A.; Ding, Y. Neuronal damage and functional deficits are ameliorated by inhibition of aquaporin
and HIF1α after traumatic brain injury (TBI). J. Neurol. Sci. 2012, 323, 134–140. [CrossRef] [PubMed]
23. Zelenina, M. Regulation of brain aquaporins. Neurochem. Int. 2010, 57, 468–488. [CrossRef] [PubMed]
24. Cartagena, C.M.; Phillips, K.L.; Tortella, F.C.; Dave, J.R.; Schmid, K.E. Temporal alterations in aquaporin
and transcription factor HIF1α expression following penetrating ballistic-like brain injury (PBBI).
Mol. Cell. Neurosci. 2014, 60, 81–87. [CrossRef] [PubMed]
25. Filippidis, A.S.; Carozza, R.B.; Rekate, H.L. Aquaporins in brain edema and neuropathological conditions.
Int. J. Mol. Sci. 2017, 18, 55. [CrossRef]
26. Simard, M.; Nedergaard, M. The neurobiology of glia in the context of water and ion homeostasis.
Neuroscience 2004, 129, 877–896. [CrossRef] [PubMed]
27. Meffre, D.; Delespierre, B.; Gouézou, M.; Leclerc, P.; Vinson, G.P.; Schumacher, M.; Stein, D.G.; Guennoun, R.
The membrane-associated progesterone-binding protein 25-Dx is expressed in brain regions involved in
water homeostasis and is up-regulated after traumatic brain injury. J. Neurochem. 2005, 93, 1314–1326.
[CrossRef] [PubMed]
28. Pop, V.; Badaut, J. A neurovascular perspective for long-term changes after brain trauma. Transl. Stroke Res.
2011, 2, 533–545. [CrossRef] [PubMed]
29. Ren, Z.; Iliff, J.J.; Yang, L.; Yang, J.; Chen, X.; Chen, M.J.; Giese, R.N.; Wang, B.; Shi, X.; Nedergaard, M. Hit &
Run model of closed-skull traumatic brain injury (TBI) reveals complex patterns of posttraumatic AQP4
dysregulation. J. Cereb. Blood Flow Metab. 2013, 33, 834–845. [PubMed]
30. Statler, K.D.; Alexander, H.; Vagni, V.; Dixon, C.E.; Clark, R.S.; Jenkins, L.; Kochanek, P.M. Comparison
of seven anesthetic agents on outcome after experimental traumatic brain injury in adult, male rats.
J. Neurotrauma 2006, 23, 97–108. [CrossRef] [PubMed]
31. Fleming, J.C.; Norenberg, M.D.; Ramsay, D.A.; Dekaban, G.A.; Marcillo, A.E.; Saenz, A.D.;
Pasquale-Styles, M.; Dietrich, W.D.; Weaver, L.C. The cellular inflammatory response in human spinal
cords after injury. Brain 2006, 129, 3249–3269. [CrossRef] [PubMed]
32. Suzuki, R.; Okuda, M.; Asai, J.; Nagashima, G.; Itokawa, H.; Matsunaga, A.; Fujimoto, T.; Suzuki, T. Astrocytes
co-express aquaporin-1, -4, and vascular endothelial growth factor in brain edema tissue associated with
brain contusion. Acta Neurochir. Suppl. 2006, 96, 398–401. [PubMed]
33. Van Landeghem, F.K.; Weiss, T.; Oehmichen, M.; von Deimling, A. Decreased expression of glutamate
transporters in astrocytes after human traumatic brain injury. J. Neurotrauma 2006, 23, 1518–1528. [CrossRef]
[PubMed]
34. Castejón, O.J. Biopathology of astrocytes in human traumatic and complicated brain injuries. Review and
hypothesis. Folia Neuropathol. 2015, 53, 173–192. [CrossRef] [PubMed]
35. Castejón, O.J. Electron microscopy of astrocyte changes and subtypes in traumatic human edematous cerebral
cortex: A review. Ultrastruct. Pathol. 2013, 37, 417–424. [CrossRef] [PubMed]
36. Lang, D.A.; Teasdale, G.M.; Macpherson, P.; Lawrence, A. Diffuse brain swelling after head injury: More
often malignant in adults than children? J. Neurosurg. 1994, 80, 675–680. [CrossRef] [PubMed]
37. Bauer, R.; Fritz, H. Pathophysiology of traumatic injury in the developing brain: An introduction and short
update. Exp. Toxicol. Pathol. 2004, 56, 65–73. [CrossRef] [PubMed]
38. Kochanek, P.M. Pediatric traumatic brain injury: Quo vadis? Dev. Neurosci. 2006, 28, 244–255. [CrossRef]
[PubMed]
39. Ito, U.; Tomita, H.; Yamazaki, S.; Takada, I.; Inaba, Y. Brain swelling and brain oedema in acute head injury.
Acta Neurochir. (Wien.) 1986, 79, 120–124. [CrossRef] [PubMed]
40. Sorani, M.D.; Manley, G.T.; Giacomini, K.M. Genetic variation in human aquaporins and effects on
phenotypes of water homeostasis. Hum. Mutat. 2008, 29, 1108–1117. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 3544 18 of 19
41. Ding, J.Y.; Kreipke, C.W.; Speirs, S.L.; Schafer, P.; Schafer, S.; Rafols, J.A. Hypoxia-inducible factor-1α
signaling in aquaporin upregulation after traumatic brain injury. Neurosci. Lett. 2009, 453, 68–72. [CrossRef]
[PubMed]
42. Hoogland, I.C.M.; Houbolt, C.; van Westerloo, D.J.; van Gool, W.A.; van de Beek, D. Systemic inflammation
and microglial activation: Systematic review of animal experiments. J. Neuroinflamm. 2015, 12, 114. [CrossRef]
[PubMed]
43. Hoogland, I.C.M.; Westhoff, D.; Engelen-Lee, J.Y.; Melief, J.; Valls Serón, M.; Houben-Weerts, J.H.M.P.;
Huitinga, I.; van Westerloo, D.J.; van der Poll, T.; van Gool, W.A.; et al. Microglial activation after systemic
stimulation with lipopolysaccharide and Escherichia coli. Front. Cell. Neurosci. 2018, 12, 110. [CrossRef]
[PubMed]
44. Yang, M.; Gao, F.; Liu, H.; Yu, W.H.; He, G.Q.; Zhuo, F.; Qiu, G.P.; Sun, S.Q. Immunolocalization of aquaporins
in rat brain. Anat. Histol. Embryol. 2011, 40, 299–306. [CrossRef] [PubMed]
45. Manley, G.T.; Fujimura, M.; Ma, T.; Noshita, N.; Filiz, F.; Bollen, A.W.; Chan, P.; Verkman, A.S. Aquaporin-4
deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat. Med. 2000, 6,
159–163. [CrossRef] [PubMed]
46. Papadopoulos, M.C.; Manley, G.T.; Krishna, S.; Verkman, A.S. Aquaporin-4 facilitates reabsorption of excess
fluid in vasogenic brain edema. FASEB J. 2004, 18, 1291–1293. [CrossRef] [PubMed]
47. Frigeri, A.; Gropper, M.A.; Umenishi, F.; Kawashima, M.; Brown, D.; Verkman, A.S. Localization of MIWC
and GLIP water channel homologs in neuromuscular, epithelial and glandular tissues. J. Cell Sci. 1995, 108,
2993–3002. [PubMed]
48. Nielsen, S.; Nagelhus, E.A.; Amiry-Moghaddam, M.; Bourque, C.; Agre, P.; Ottersen, O.P. Specialized
membrane domains for water transport in glial cells: High-resolution immunogold cytochemistry of
aquaporin-4 in rat brain. J. Neurosci. 1997, 17, 171–180. [CrossRef] [PubMed]
49. Verkman, A.S. Aquaporins: Translating bench research to human disease. J. Exp. Biol. 2009, 212, 1707–1715.
[CrossRef] [PubMed]
50. Wolburg, H.; Noell, S.; Fallier-Becker, P.; Mack, A.F.; Wolburg-Buchholz, K. The disturbed blood-brain barrier
in human glioblastoma. Mol. Aspects Med. 2012, 33, 579–589. [CrossRef] [PubMed]
51. Steiner, E.; Enzmann, G.U.; Lin, S.; Ghavampour, S.; Hannocks, M.J.; Zuber, B.; Rüegg, M.A.; Sorokin, L.;
Engelhardt, B. Loss of astrocyte polarization upon transient focal brain ischemia as a possible mechanism to
counteract early edema formation. Glia 2012, 60, 1646–1659. [CrossRef] [PubMed]
52. Fukuda, A.M.; Pop, V.; Spagnoli, D.; Ashwal, S.; Obenaus, A.; Badaut, J. Delayed increase of astrocytic
aquaporin 4 after juvenile traumatic brain injury: Possible role in edema resolution? Neuroscience 2012, 222,
366–378. [CrossRef] [PubMed]
53. Rash, J.E.; Yasumura, T.; Hudson, C.S.; Agre, P.; Nielsen, S. Direct immunogold labeling of aquaporin-4 in
square arrays of astrocyte and ependymocyte plasma membranes in rat brain and spinal cord. Proc. Natl.
Acad. Sci. USA 1998, 95, 11981–11986. [CrossRef] [PubMed]
54. Tang, G.; Yang, G.Y. Aquaporin-4: A potential therapeutic target for cerebral edema. Int. J. Mol. Sci. 2016, 17,
1413. [CrossRef]
55. Rao, K.V.; Reddy, P.; Curtis, K.M.; Norenberg, M.D. Aquaporin-4 expression in cultured astrocytes after fluid
percussion injury. J. Neurotrauma 2011, 28, 371–381. [CrossRef] [PubMed]
56. Stokum, J.A.; Kurland, D.B.; Gerzanich, V.; Simard, J.M. Mechanisms of astrocyte-mediated cerebral edema.
Neurochem. Res. 2015, 40, 317–328. [CrossRef] [PubMed]
57. Papadopoulos, M.; Verkman, A.S. Aquaporin-4 gene disruption in mice reduces brain swelling and mortality
in pneumococcal meningitis. J. Biol. Chem. 2005, 280, 13906–13912. [CrossRef] [PubMed]
58. Pinchi, E.; Frati, A.; Cipolloni, L.; Aromatario, M.; Gatto, V.; La Russa, R.; Pesce, A.; Santurro, A.; Fraschetti, F.;
Frati, P.; et al. Clinical-pathological study on β-APP, IL-1β, GFAP, NFL, Spectrin II, 8OHdG, TUNEL, miR-21,
miR-16, miR-92 expressions to verify DAI-diagnosis, grade and prognosis. Sci. Rep. 2018, 8, 2387. [CrossRef]
[PubMed]
59. Frati, A.; Cerretani, D.; Fiaschi, A.-I.; Frati, P.; Gatto, V.; La Russa, R.; Pesce, A.; Pinchi, E.; Santurro, A.;
Fraschetti, F.; et al. Diffuse axonal injury and oxidative stress: A comprehensive review. Int. J. Mol. Sci. 2017,
18, 2600. [CrossRef] [PubMed]
60. Fukuda, A.M.; Badaut, J. Aquaporin 4: A player in cerebral edema and neuroinflammation. J. Neuroinflamm.
2012, 9, 279. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 3544 19 of 19
61. Marklund, N.; Bakshi, A.; Castelbuono, D.J.; Conte, V.; McIntosh, T.K. Evaluation of pharmacological
treatment strategies in traumatic brain injury. Curr. Pharm. Des. 2006, 12, 1645–1680. [CrossRef] [PubMed]
62. Li, G.; He, X.; Li, H.; Wu, Y.; Guan, Y.; Liu, S.; Jia, H.; Li, Y.; Wang, L.; Huang, R.; et al. Overexpression of
Slit2 improves function of the paravascular pathway in the aging mouse brain. Int. J. Mol. Sci. 2018, 42,
1935–1944. [CrossRef] [PubMed]
63. Dai, W.; Yan, J.; Chen, G.; Hu, G.; Zhou, X.; Zeng, X. AQP4-knockout alleviates the
lipopolysaccharide-induced inflammatory response in astrocytes via SPHK1/MAPK/AKT signaling. Int. J.
Mol. Sci. 2018, 42, 1716–1722. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
